Chrisanthi A Karanikas
Overview
Explore the profile of Chrisanthi A Karanikas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
580
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bergman B, Rosenstock J, Garvey W, Batterham R, Chen Y, Liu M, et al.
Diabetes Obes Metab
. 2025 Mar;
PMID: 40083081
Aims: This participant-level exploratory analysis assessed the continuous time spent in glycaemic control and/or with sustained weight reductions with tirzepatide treatment in participants with type 2 diabetes (T2D) from the...
2.
Tchang B, Mihai A, Stefanski A, Garcia-Perez L, Mojdami D, Jouravskaya I, et al.
Obesity (Silver Spring)
. 2025 Mar;
PMID: 40074721
Objective: Increases in adiposity and adverse changes in adipose distribution commonly occur in women during midlife and with the onset of menopause. This post hoc analysis assessed body weight changes...
3.
Peters A, Buzzetti R, Lee C, Pavo I, Liu M, Karanikas C, et al.
J Clin Endocrinol Metab
. 2024 Jun;
PMID: 38824910
Context: People with clinically diagnosed type 2 diabetes (T2D) but positive anti-glutamic acid decarboxylase autoantibodies (GADA), referred to here as latent autoimmune diabetes in adults (LADA), may experience more rapid...
4.
Rosenstock J, Lee C, Lando L, Liu M, Karanikas C, Thieu V
Diabetes Obes Metab
. 2023 Oct;
26(1):396-399.
PMID: 37880822
No abstract available.
5.
Pedersen S, Giorgino F, Umpierrez G, Thieu V, Rodriguez A, Nicolay C, et al.
Diabetes Obes Metab
. 2023 May;
25(9):2553-2560.
PMID: 37246796
Aim: To assess the relationship between HbA1c and body weight reductions with tirzepatide treatment (5, 10 or 15 mg). Materials And Methods: HbA1c and body weight data at 40 weeks...
6.
Heise T, DeVries J, Urva S, Li J, Pratt E, Thomas M, et al.
Diabetes Care
. 2023 Mar;
46(5):998-1004.
PMID: 36857477
Objective: To evaluate the effects of tirzepatide on body composition, appetite, and energy intake to address the potential mechanisms involved in body weight loss with tirzepatide. Research Design And Methods:...
7.
Rosenstock J, Wysham C, Frias J, Kaneko S, Lee C, Lando L, et al.
Lancet
. 2021 Jun;
398(10295):143-155.
PMID: 34186022
Background: Despite advancements in care, many people with type 2 diabetes do not meet treatment goals; thus, development of new therapies is needed. We aimed to assess efficacy, safety, and...
8.
Hartman M, Sanyal A, Loomba R, Wilson J, Nikooienejad A, Bray R, et al.
Diabetes Care
. 2020 Apr;
43(6):1352-1355.
PMID: 32291277
Objective: To determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of nonalcoholic steatohepatitis (NASH) and fibrosis in patients with...
9.
Patel H, Munir K, Sutherland S, Karanikas C, Konig M
Diabetes Ther
. 2019 Oct;
10(6):2321-2330.
PMID: 31605302
Introduction: The ADA-EASD consensus report recommends using glucagon-like peptide-1 receptor agonists (GLP-1RAs) as the first injectable therapy prior to basal insulin in most patients with type 2 diabetes (T2D) not...
10.
Boye K, Riddle M, Gerstein H, Mody R, Garcia-Perez L, Karanikas C, et al.
Diabetes Obes Metab
. 2019 Feb;
21(6):1299-1304.
PMID: 30714309
Aim: To examine the generalizability of results from glucagon-like peptide-1 receptor agonist (GLP-1 RA) cardiovascular outcome trials (CVOTs) in the US type 2 diabetes (T2D) population. Materials And Methods: Patients...